Technological Innovation: The rapid pace of technological innovation in single cell isolation, sequencing, and analysis techniques is a primary driver of market growth. These advancements have ...

The global single cell multiomics market is set to experience a remarkable growth trajectory, projected to reach $14,369.5 million by 2031, with an impressive Compound Annual Growth Rate (CAGR) of ...

Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced that the Patent Trial and Appeal Board (PTAB) of the United States Patent and ...

Parse Biosciences has announced an expansion of its Evercode™ WT Mega Kit functionality. The company says researchers can now analyze up to 384 samples and one million cells in a single run, unlocking ...

Parse Biosciences, a leader in accessible and scalable single cell sequencing solutions, today announced a significant expansion of its Evercode™ WT Mega Kit functionality. Researchers can now ...

In a report released today, David Amsellem from Piper Sandler reiterated a Buy rating on Teva Pharmaceutical (TEVA – Research Report), with a ...

In this edition of “Rising High,” The Fly conducted an exclusive interview with Erez Aminov, Chairman & Chief Executive Officer of MIRA ...

Swedish immuno-oncology firm Alligator Bioscience (STO: ATORX) saw its shares jump more than 13% to 0.26 kronor this morning, as it announced the positive outcome of regulatory interactions with the ...

The Midlands Integrative Biosciences Training Partnership is a BBSRC-funded doctoral training partnership between the universities of Warwick, Birmingham, Leicester, Aston, Harper Adams and Coventry.

In a move that blurs the line between science fiction and reality, Colossal Biosciences, the pioneering de-extinction company backed by countless celebs, has secured $200 million in Series C funding.

Colossal Biosciences, the company that’s famously on a mission to bring back the woolly mammoth and two other extinct species, has raised a $200 million Series C at a $10.2 billion valuation ...